Banca de DEFESA: FERNANDA MATOS FONTENELLE

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
DISCENTE : FERNANDA MATOS FONTENELLE
DATA : 16/06/2021
HORA: 17:30
LOCAL: PLATAFORMA GOOGLE MEET
TÍTULO:

Adherence to drug treatment in children and adolescents with cystic fibrosis: evaluation by two methods.

PALAVRAS-CHAVES:

Mucoviscidosis. Therapeutic compliance. Medication. Complexity.

PÁGINAS: 118
GRANDE ÁREA: Ciências da Saúde
ÁREA: Farmácia
RESUMO:

Cystic fibrosis (CF) is an inherited, autosomal recessive disease caused by mutations in Cystic Fibrosis Transmembrane Regulator (CFTR) gene. It encodes the protein of the same name (CFTR) that is responsible for transporting ions through the membranes of epithelial cells from exocrine glands in tissues of various organs, which is followed by thickening of mucous secretions and thus organic dysfunctions. Due to the its multisystemic, chronic and progressive character, CF requires a long and complex daily treatment, which can make difficult the adherence to treatment (AT). Objectives: to assess self-reported adherence to treatment (AT) and the one based on drug dispensing records by pharmacy and to analyze factors associated with better AT in children and adolescents with CF. Methods: A cross-sectional study was carried out by using two methodologies to assess AT in CF. Morisky-Green test was applied to measure self-reported AT. Morisky-Green test divides participants into two groups: adherence and non-adherence. The amount of use of dispensed medicines was evaluated based on pharmacy dispensation records and medical prescription. Percentage of use of dispensed medicines by pharmacy equal to or greater than 80% was classified as good AT. In order to assess association between good AT and sociodemographic and clinical variables, prevalence ratios (PR) were calculated. AT correlation rate that was measured by the two methods was also calculated. Results: 43 participants were included, 55.8% female, median age (Q1,Q3) 7.3 years (3.4 , 12.4). There was self-reported AT for the use of pancreatic enzymes, alfadornase and continuous use of tobramycin inhalation which indicated, respectively, 65.8%; 50.0% and 44.4% among participants. Percentage for use of dispensed medicines by pharmacy was 69.0%; 66.7%, 52.6%, for use of alfadornase, for continuous use of tobramycin and pancreatic enzymes, respectively. When comparing the two methods, correlation rates for each medication were: 64.0%, 75.0% and 85.7%, for pancreatin, continuous use of tobramycin and alfadornase, respectively. There was a greater association between self-reported AT to the use of pancreatic enzymes and child's current age below 14 years (PR = 2.15), lower education level of those who administered the medication (PR = 1.63), receiving INSS benefit for chronic diseases (PR = 1.46), female sex (PR = 1.34) and monthly family income of up to 01 minimum wage (PR = 1.27). There was a greater association between AT with use of dornase alfa and lower education level of the person responsible for administering the treatment (PR 1.54) and current age less than 14 years (PR 1.46). Conclusions: We obtained low percentages of AT through the use of two methodologies. AT rates were variable with the medication that was used and they were associated with the participant low age for all the medications in evaluation.

MEMBROS DA BANCA:
Externo(a) à Instituição - ANIBAL DE FREITAS SANTOS JUNIOR - UNEB
Presidente - 287531 - EDNA LUCIA SANTOS DE SOUZA
Externo(a) ao Programa - 2556460 - PABLO DE MOURA SANTOS